Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X:
“JAMA Oncology: ctDNA MRD after CRLM resection identifies who benefits from ACT!
Upfront surgery: MRD+ patients improved with ACT (DFS HR 0.07 and OS HR 0.27 vs observation). MRD- patients showed no benefit.
This supports selective ACT use and explains why prior trials lacked consistent OS benefit due to mixed patient groups without biomarker stratification.
Would ctDNA MRD change how you decide on adjuvant chemo for resected CRLM patients?”
Title: Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
Authors: Kozo Kataoka, Kazuma Ito, Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, Jun Nagata, Mitsuru Yokota, Kentaro Kato, Masahito Kotaka, Tadayoshi Hashimoto, Kentaro Yamazaki, Yoshinori Kagawa, Saori Mishima, Koji Ando, Masaaki Miyo, Hiroki Yukami, Arkarachai Fungtammasan, Shruti Sharma, J. Bryce Ortiz, Matthew Rabinowitz, Robert W. Lentz, Adham Jurdi, Minetta C. Liu, Alexey Aleshin, Daisuke Kotani, Hideaki Bando, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Takayuki Yoshino, Eiji Oki for the CIRCULATE-Japan Group
Other articles featuring Parham Habibzadeh on OncoDaily.